HRP20110694T1 - Novi spojevi kao modulatori opioidnog receptora - Google Patents

Novi spojevi kao modulatori opioidnog receptora Download PDF

Info

Publication number: HRP20110694T1
Authority: HR; Croatia
Prior art keywords: alkyl; group; aryl; optionally substituted; phenyl
Prior art date: 2004-03-15

Application number

HR20110694T

Other languages

English (en)

Croatian (hr)

Inventor

J. Breslin Henry

Cai Chaozhong

He Wei

W. Kavash Robert

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-15

Filing date

2011-09-28

Publication date

2011-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110694(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-28 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2011-12-31 Publication of HRP20110694T1 publication Critical patent/HRP20110694T1/hr

Links

150000001875 compounds Chemical class 0.000 title claims abstract 49
102000003840 Opioid Receptors Human genes 0.000 title 1
108090000137 Opioid Receptors Proteins 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims abstract 55
125000003118 aryl group Chemical group 0.000 claims abstract 53
125000001424 substituent group Chemical group 0.000 claims abstract 53
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 47
125000001072 heteroaryl group Chemical group 0.000 claims abstract 37
-1 hydroxy, cyano, amino Chemical group 0.000 claims abstract 37
229910052739 hydrogen Inorganic materials 0.000 claims abstract 33
239000001257 hydrogen Substances 0.000 claims abstract 33
125000000623 heterocyclic group Chemical group 0.000 claims abstract 17
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 16
125000000753 cycloalkyl group Chemical group 0.000 claims abstract 11
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 10
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 49
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 38
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 34
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 28
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 16
125000003545 alkoxy group Chemical group 0.000 claims 16
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 15
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 15
229910052736 halogen Inorganic materials 0.000 claims 15
150000002367 halogens Chemical class 0.000 claims 15
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 14
125000005100 aryl amino carbonyl group Chemical group 0.000 claims 14
229910052799 carbon Inorganic materials 0.000 claims 14
125000004093 cyano group Chemical group *C#N 0.000 claims 14
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 12
125000002541 furyl group Chemical group 0.000 claims 11
125000004076 pyridyl group Chemical group 0.000 claims 11
208000002193 Pain Diseases 0.000 claims 10
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
150000002431 hydrogen Chemical class 0.000 claims 10
229910052757 nitrogen Inorganic materials 0.000 claims 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 9
125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 claims 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 7
125000005553 heteroaryloxy group Chemical group 0.000 claims 7
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
125000001309 chloro group Chemical group Cl* 0.000 claims 6
125000001153 fluoro group Chemical group F* 0.000 claims 6
150000003839 salts Chemical class 0.000 claims 6
125000004104 aryloxy group Chemical group 0.000 claims 5
125000001246 bromo group Chemical group Br* 0.000 claims 5
125000005241 heteroarylamino group Chemical group 0.000 claims 5
125000003831 tetrazolyl group Chemical group 0.000 claims 5
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
125000000304 alkynyl group Chemical group 0.000 claims 4
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
125000001769 aryl amino group Chemical group 0.000 claims 4
125000004433 nitrogen atom Chemical group N* 0.000 claims 4
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 3
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims 3
230000001404 mediated effect Effects 0.000 claims 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 3
125000002950 monocyclic group Chemical group 0.000 claims 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 2
125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims 2
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
206010012735 Diarrhoea Diseases 0.000 claims 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
229910052801 chlorine Inorganic materials 0.000 claims 2
239000000460 chlorine Substances 0.000 claims 2
125000000000 cycloalkoxy group Chemical group 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
208000035475 disorder Diseases 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
208000002551 irritable bowel syndrome Diseases 0.000 claims 2
238000000034 method Methods 0.000 claims 2
208000004296 neuralgia Diseases 0.000 claims 2
208000021722 neuropathic pain Diseases 0.000 claims 2
125000006513 pyridinyl methyl group Chemical group 0.000 claims 2
208000011580 syndromic disease Diseases 0.000 claims 2
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
QFNHIDANIVGXPE-UHFFFAOYSA-N 5-[[[2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[1-(5-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC=C1CN(C(=O)C(N)CC=1C(=CC(=CC=1C)C(N)=O)C)C(C)C1=NC(C=2C=CC=CC=2)=CN1 QFNHIDANIVGXPE-UHFFFAOYSA-N 0.000 claims 1
125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
208000006561 Cluster Headache Diseases 0.000 claims 1
206010009900 Colitis ulcerative Diseases 0.000 claims 1
206010010774 Constipation Diseases 0.000 claims 1
208000011231 Crohn disease Diseases 0.000 claims 1
208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
208000018522 Gastrointestinal disease Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
206010027603 Migraine headaches Diseases 0.000 claims 1
206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
206010054048 Postoperative ileus Diseases 0.000 claims 1
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 claims 1
208000026137 Soft tissue injury Diseases 0.000 claims 1
208000037386 Typhoid Diseases 0.000 claims 1
201000006704 Ulcerative Colitis Diseases 0.000 claims 1
208000005298 acute pain Diseases 0.000 claims 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
108700023159 delta Opioid Receptors Proteins 0.000 claims 1
102000048124 delta Opioid Receptors Human genes 0.000 claims 1
208000010643 digestive system disease Diseases 0.000 claims 1
208000018685 gastrointestinal system disease Diseases 0.000 claims 1
125000002883 imidazolyl group Chemical group 0.000 claims 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
125000001041 indolyl group Chemical group 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
230000004899 motility Effects 0.000 claims 1
102000051367 mu Opioid Receptors Human genes 0.000 claims 1
125000002971 oxazolyl group Chemical group 0.000 claims 1
210000001428 peripheral nervous system Anatomy 0.000 claims 1
208000037821 progressive disease Diseases 0.000 claims 1
125000003373 pyrazinyl group Chemical group 0.000 claims 1
125000003226 pyrazolyl group Chemical group 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
125000000168 pyrrolyl group Chemical group 0.000 claims 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
229910052717 sulfur Inorganic materials 0.000 claims 1
125000000335 thiazolyl group Chemical group 0.000 claims 1
125000001544 thienyl group Chemical group 0.000 claims 1
206010044652 trigeminal neuralgia Diseases 0.000 claims 1
201000008297 typhoid fever Diseases 0.000 claims 1
108020001612 μ-opioid receptors Proteins 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

HR20110694T 2004-03-15 2011-09-28 Novi spojevi kao modulatori opioidnog receptora HRP20110694T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55334204P	2004-03-15	2004-03-15
PCT/US2005/008339 WO2005090315A1 (en)	2004-03-15	2005-03-14	Novel compounds as opioid receptor modulators

Publications (1)

Publication Number	Publication Date
HRP20110694T1 true HRP20110694T1 (hr)	2011-12-31

Family

ID=34962827

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
HR20110694T HRP20110694T1 (hr)	2004-03-15	2011-09-28	Novi spojevi kao modulatori opioidnog receptora
HRP20130800TT HRP20130800T1 (en)	2004-03-15	2013-08-22	Opioid receptor modulators
HRP20150305TT HRP20150305T1 (hr)	2004-03-15	2015-03-18	Postupak za pripravu intermedijera spojeva korisnih kao modulatori opioid receptora
HRP20161331TT HRP20161331T1 (hr)	2004-03-15	2016-10-12	Modulatori opioidnih receptora

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
HRP20130800TT HRP20130800T1 (en)	2004-03-15	2013-08-22	Opioid receptor modulators
HRP20150305TT HRP20150305T1 (hr)	2004-03-15	2015-03-18	Postupak za pripravu intermedijera spojeva korisnih kao modulatori opioid receptora
HRP20161331TT HRP20161331T1 (hr)	2004-03-15	2016-10-12	Modulatori opioidnih receptora

Country Status (36)

Country	Link
US (8)	US7741356B2 (es)
EP (5)	EP2298744B1 (es)
JP (1)	JP4778954B2 (es)
KR (1)	KR101166342B1 (es)
CN (2)	CN1950342B (es)
AR (2)	AR048269A1 (es)
AT (1)	ATE516274T1 (es)
AU (1)	AU2005224091B2 (es)
BR (1)	BRPI0508820B8 (es)
CA (1)	CA2560047C (es)
CR (1)	CR8655A (es)
CY (3)	CY1111927T1 (es)
DK (5)	DK2298744T3 (es)
EC (1)	ECSP066856A (es)
ES (5)	ES2705077T3 (es)
HK (4)	HK1099016A1 (es)
HR (4)	HRP20110694T1 (es)
HU (2)	HUE029852T2 (es)
IL (3)	IL178040A (es)
LT (2)	LT2653465T (es)
LU (1)	LUC00007I2 (es)
ME (3)	ME02221B (es)
MX (1)	MXPA06010642A (es)
MY (1)	MY146972A (es)
NL (1)	NL300865I2 (es)
NO (3)	NO338203B1 (es)
NZ (1)	NZ549842A (es)
PH (1)	PH12012501640B1 (es)
PL (4)	PL2653465T3 (es)
PT (4)	PT1725537E (es)
RS (4)	RS55122B1 (es)
SI (4)	SI2298744T1 (es)
TW (1)	TWI361069B (es)
UA (1)	UA86053C2 (es)
WO (1)	WO2005090315A1 (es)
ZA (1)	ZA200608587B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
PL2653465T3 (pl) *	2004-03-15	2017-01-31	Janssen Pharmaceutica Nv	Modulatory receptora opioidowego
CN1984879B (zh)	2004-05-14	2011-07-27	詹森药业有限公司	甲酰胺基阿片样化合物
AR052051A1 (es)	2004-12-15	2007-02-28	Neuralab Ltd	Anticuerpos ab humanizados usados en mejorar la cognicion
JP2008533141A (ja) *	2005-03-14	2008-08-21	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	オピオイド調節物質の製造方法
AR058379A1 (es) *	2005-12-14	2008-01-30	Bristol Myers Squibb Co	Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
SG170767A1 (en) *	2005-12-23	2011-05-30	Zealand Pharma As	Modified lysine-mimetic compounds
MX2008012991A (es)	2006-04-07	2008-10-17	Procter & Gamble	Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US7622593B2 (en)	2006-06-27	2009-11-24	The Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
PL2468724T3 (pl)	2006-12-21	2016-05-31	Zealand Pharma As	Synteza związków pirolidynowych
ES2567077T3 (es)	2007-07-09	2016-04-19	Forest Tosara Limited	Cristales novedosos y proceso de 5-({[2-amino-3-(4-carbamoil-2,6-dimetil-fenil)propionil]-[1-(4-fenil-1H-imidazol-2-il)-etil] amino}metil)-2-metoxi-benzoico
PL2182983T3 (pl)	2007-07-27	2014-10-31	Janssen Alzheimer Immunotherap	Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh)	2008-10-27	2015-01-11	Janssen Pharmaceutica Nv	製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
JP5198220B2 (ja) *	2008-11-13	2013-05-15	東ソ−・エフテック株式会社	アミノ酸誘導体の製造方法
PT2451279T (pt)	2009-07-06	2019-06-18	Aerpio Therapeutics Inc	Derivados de benzosulfonamida, composições dos mesmos, e uso dos mesmos na prevenção de metástases de células cancerígenas
WO2012155199A1 (en)	2011-05-16	2012-11-22	Bionomics Limited	Amine derivatives as potassium channel blockers
EP2524912A1 (en)	2011-05-16	2012-11-21	Bionomics Limited	Amine derivatives
AU2012323856B2 (en)	2011-10-13	2017-05-25	EyePoint Pharmaceuticals, Inc.	Methods for treating Vascular Leak Syndrome and cancer
CN105339351B (zh)	2013-03-14	2018-11-06	Epizyme股份有限公司	精氨酸甲基转移酶抑制剂及其用途
US9675587B2 (en)	2013-03-14	2017-06-13	Allergan Holdings Unlimited Company	Opioid receptor modulator dosage formulations
US9447079B2 (en) *	2013-03-14	2016-09-20	Epizyme, Inc.	PRMT1 inhibitors and uses thereof
US9023883B2 (en)	2013-03-14	2015-05-05	Epizyme, Inc.	PRMT1 inhibitors and uses thereof
US9120757B2 (en)	2013-03-14	2015-09-01	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
US20150050277A1 (en)	2013-03-15	2015-02-19	Aerpio Therapeutics Inc.	Compositions and methods for treating ocular diseases
JP6483148B2 (ja)	2014-03-14	2019-03-13	エアーピオセラピューティクスインコーポレイテッド	ＨＰＴＰ−β阻害剤
IS2977B (is)	2015-02-23	2017-07-15	Actavis Group Ptc Ehf.	Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017007695A1 (en)	2015-07-09	2017-01-12	The Regents Of The University Of California	Mu opioid receptor modulators
US10314819B2 (en)	2015-07-23	2019-06-11	Teva Pharmaceuticals International Gmbh	Solid state forms of Eluxadoline
CN108026032B (zh) *	2015-09-11	2020-09-29	株式会社钟化	光学活性4-氨基甲酰基-2,6-二甲基苯基丙氨酸衍生物的制造方法
JP6959924B2 (ja)	2015-09-23	2021-11-05	エアーピオファーマシューティカルズ，インコーポレイテッド	Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法
CN105250232B (zh) *	2015-09-29	2018-08-14	江苏汇智知识产权服务有限公司	一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) *	2015-12-31	2017-07-06	苏州晶云药物科技有限公司	艾沙度林的新晶型及其制备方法
CN107129444B (zh) *	2016-02-29	2018-08-31	尚科生物医药（上海）有限公司	(s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
EP3272741A1 (en)	2016-07-21	2018-01-24	Euticals S.P.A.	New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) *	2016-03-28	2018-01-02	成都伊诺达博医药科技有限公司	丙氨酸衍生物的制备方法
CN105693554B (zh) *	2016-04-06	2017-08-08	成都伊诺达博医药科技有限公司	丙氨酸衍生物的制备方法
WO2017191650A1 (en) *	2016-05-03	2017-11-09	Msn Laboratories Private Limited	Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
MA45184A (fr) *	2016-05-30	2019-04-10	Sun Pharmaceutical Ind Ltd	Procédé de préparation de l'éluxadoline .
EP3474847B1 (en) *	2016-06-23	2022-09-07	Sun Pharmaceutical Industries Limited	Processes for the preparation of eluxadoline
WO2018020450A2 (en)	2016-07-28	2018-02-01	Lupin Limited	Process for the preparation of eluxadoline
CZ2016548A3 (cs)	2016-09-07	2018-03-14	Zentiva, K.S.	Pevné formy eluxadolinu
WO2018047131A1 (en) *	2016-09-09	2018-03-15	Sun Pharmaceutical Industries Limited	Amorphous eluxadoline
WO2018055528A2 (en) *	2016-09-20	2018-03-29	Sun Pharmaceutical Industries Limited	Processes for the preparation of eluxadoline
US10738013B2 (en)	2017-01-27	2020-08-11	Quimica Sintetica, S.A.	Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en)	2017-01-27	2018-08-02	Quimica Sintetica, S. A.	Eluxadoline crystalline form and process for the preparation thereof
CN110709096B (zh)	2017-05-05	2023-10-31	泽兰德制药公司	细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
WO2019008604A1 (en)	2017-07-07	2019-01-10	Cipla Limited	NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) *	2018-01-25	2019-08-01	四川科伦博泰生物医药股份有限公司	取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en)	2018-04-09	2019-10-17	Quimica Sintetica, S. A.	Process for the preparation of opioid modulators
WO2020039333A1 (en)	2018-08-20	2020-02-27	Allergan Holdings Unlimited Company	Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
EP3856245A4 (en)	2018-09-24	2022-10-26	EyePoint Pharmaceuticals, Inc.	MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF
EP3659433B1 (de) *	2018-11-30	2021-01-20	Phytobiotics Futterzusatzstoffe GmbH	System zur analyse von tierausscheidungsbildern
CN111377832A (zh) *	2018-12-27	2020-07-07	江苏联昇化学有限公司	一种伊卢多啉中间体制备的新方法
CA3138682A1 (en)	2019-04-29	2020-11-05	EyePoint Pharmaceuticals, Inc.	Tie-2 activators targeting the schlemm's canal
WO2021198780A1 (en)	2020-03-30	2021-10-07	Allergan Holdings Unlimited Company	Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
US20220041595A1 (en) *	2020-07-28	2022-02-10	Jazz Pharmaceuticals Ireland Limited	Chiral synthesis of fused bicyclic raf inhibitors
US20220096676A1 (en)	2020-09-29	2022-03-31	Abl Ip Holding Llc	Techniques for Directing Ultraviolet Energy Towards a Moving Surface
US11850319B2 (en)	2020-09-29	2023-12-26	Abl Ip Holding Llc	Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) *	2020-11-27	2022-03-11	成都泰蓉生物科技有限公司	一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD142804A3 (de) *	1977-11-07	1980-07-16	Wagner Guenter	Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) *	1987-12-31	1989-11-07	Monsanto Company	Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv)	1994-08-30	1994-08-30	Astra Ab	New peptide derivatives
UA55381C2 (uk) *	1995-01-27	2003-04-15	Ново Нордіск А/С	Похідні пептиду (варіанти), що здатні вивільнювати гормон росту, фармацевтична композиція (варіанти), спосіб стимулювання вивільнення гормону росту з гіпофіза, способи підвищення швидкості і темпу росту та виробництва молока або вовни, спосіб лікування нездужань
US5565568A (en)	1995-04-06	1996-10-15	Eli Lilly And Company	2-acylaminopropanamides as tachykinin receptor antagonists
CA2217006C (en)	1995-04-13	2001-05-22	Hoechst Marion Roussel, Inc.	Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
EP0761220A1 (en)	1995-08-21	1997-03-12	Eli Lilly And Company	2-Acylaminopropanamides as growth hormone secretagogues
AU7710596A (en)	1995-11-29	1997-06-19	Nihon Nohyaku Co., Ltd.	Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en)	1997-04-23	1998-08-11	Eli Lilly And Company	Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it)	1998-09-08	2001-04-05	Menarini Ricerche Spa	Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
DE60006032T2 (de) *	1999-05-28	2004-06-17	Pfizer Products Inc., Groton	3-(3-Hydroxyphenyl)-3-amino-propionamidderivate
FR2796643B1 (fr)	1999-07-22	2005-04-29	Sod Conseils Rech Applic	Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en)	2000-08-31	2000-10-18	Oxford Glycosciences Uk Ltd	Compounds
US20020072017A1 (en) *	2000-10-19	2002-06-13	Hudnall Phillip Montgomery	Stabilized p-phenylenediamine-type photographic color developers in free base form
ATE363276T1 (de)	2000-10-30	2007-06-15	Janssen Pharmaceutica Nv	Tripeptidylpeptidase-hemmer
DE60216627T2 (de) *	2001-10-15	2007-09-20	Janssen Pharmaceutica N.V.	Neue substituierte 4-phenyl-4-ä1h-imidazo-2-ylü-piperidin-derivate und ihre anwendung als selective delta-opioid-agonisten
US7041681B2 (en)	2002-04-29	2006-05-09	Janssen Pharmaceutica N.V.	Compounds as opioid receptor modulators
PL2653465T3 (pl)	2004-03-15	2017-01-31	Janssen Pharmaceutica Nv	Modulatory receptora opioidowego
EP1753749B1 (en)	2004-05-03	2014-07-30	Janssen Pharmaceutica NV	Novel indole derivatives as selective androgen receptor modulators (sarms)
JP2008533141A (ja) *	2005-03-14	2008-08-21	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	オピオイド調節物質の製造方法

2005
- 2005-03-14 PL PL13173454T patent/PL2653465T3/pl unknown
- 2005-03-14 PL PL12194058T patent/PL2573068T3/pl unknown
- 2005-03-14 WO PCT/US2005/008339 patent/WO2005090315A1/en active Application Filing
- 2005-03-14 DK DK10182349.0T patent/DK2298744T3/da active
- 2005-03-14 DK DK05728171.9T patent/DK1725537T3/da active
- 2005-03-14 RS RS20160843A patent/RS55122B1/sr unknown
- 2005-03-14 JP JP2007503986A patent/JP4778954B2/ja not_active Expired - Fee Related
- 2005-03-14 US US11/079,647 patent/US7741356B2/en active Active
- 2005-03-14 HU HUE13173454A patent/HUE029852T2/en unknown
- 2005-03-14 SI SI200531771T patent/SI2298744T1/sl unknown
- 2005-03-14 EP EP10182349.0A patent/EP2298744B1/en active Active
- 2005-03-14 RS RS20130371A patent/RS52933B/en unknown
- 2005-03-14 AT AT05728171T patent/ATE516274T1/de active
- 2005-03-14 ME MEP-2015-36A patent/ME02221B/me unknown
- 2005-03-14 TW TW094107612A patent/TWI361069B/zh not_active IP Right Cessation
- 2005-03-14 EP EP16178050.7A patent/EP3112352B1/en active Active
- 2005-03-14 DK DK13173454.3T patent/DK2653465T3/da active
- 2005-03-14 SI SI200531383T patent/SI1725537T1/sl unknown
- 2005-03-14 ME MEP-2013-97A patent/ME01601B/me unknown
- 2005-03-14 KR KR1020067021231A patent/KR101166342B1/ko active IP Right Grant
- 2005-03-14 PT PT05728171T patent/PT1725537E/pt unknown
- 2005-03-14 RS RS20110446A patent/RS51995B/en unknown
- 2005-03-14 ES ES16178050T patent/ES2705077T3/es active Active
- 2005-03-14 BR BRPI0508820A patent/BRPI0508820B8/pt not_active IP Right Cessation
- 2005-03-14 CN CN200580014571XA patent/CN1950342B/zh not_active Expired - Fee Related
- 2005-03-14 EP EP05728171A patent/EP1725537B1/en active Active
- 2005-03-14 PT PT131734543T patent/PT2653465T/pt unknown
- 2005-03-14 EP EP12194058.9A patent/EP2573068B9/en active Active
- 2005-03-14 NZ NZ549842A patent/NZ549842A/en not_active IP Right Cessation
- 2005-03-14 SI SI200531934T patent/SI2573068T1/sl unknown
- 2005-03-14 MX MXPA06010642A patent/MXPA06010642A/es active IP Right Grant
- 2005-03-14 UA UAA200609824A patent/UA86053C2/ru unknown
- 2005-03-14 RS RS20150204A patent/RS54199B1/en unknown
- 2005-03-14 MY MYPI20051060A patent/MY146972A/en unknown
- 2005-03-14 SI SI200532091A patent/SI2653465T1/sl unknown
- 2005-03-14 DK DK12194058.9T patent/DK2573068T3/en active
- 2005-03-14 PT PT101823490T patent/PT2298744E/pt unknown
- 2005-03-14 ES ES05728171T patent/ES2367576T3/es active Active
- 2005-03-14 ME MEP-2016-232A patent/ME02540B/me unknown
- 2005-03-14 PL PL05728171T patent/PL1725537T3/pl unknown
- 2005-03-14 ES ES13173454.3T patent/ES2596434T3/es active Active
- 2005-03-14 CN CN201210277845.6A patent/CN102786476B/zh not_active Expired - Fee Related
- 2005-03-14 PL PL10182349T patent/PL2298744T3/pl unknown
- 2005-03-14 PT PT121940589T patent/PT2573068E/pt unknown
- 2005-03-14 CA CA2560047A patent/CA2560047C/en active Active
- 2005-03-14 EP EP13173454.3A patent/EP2653465B1/en active Active
- 2005-03-14 AU AU2005224091A patent/AU2005224091B2/en not_active Ceased
- 2005-03-14 DK DK16178050.7T patent/DK3112352T3/en active
- 2005-03-14 ES ES12194058.9T patent/ES2533176T3/es active Active
- 2005-03-14 ES ES10182349T patent/ES2428008T3/es active Active
- 2005-03-14 LT LTEP13173454.3T patent/LT2653465T/lt unknown
- 2005-03-15 AR ARP050101007A patent/AR048269A1/es active IP Right Grant
2006
- 2006-09-12 IL IL178040A patent/IL178040A/en active IP Right Grant
- 2006-09-15 EC EC2006006856A patent/ECSP066856A/es unknown
- 2006-09-25 CR CR8655A patent/CR8655A/es unknown
- 2006-10-13 ZA ZA2006/08587A patent/ZA200608587B/en unknown
- 2006-10-13 NO NO20064660A patent/NO338203B1/no not_active IP Right Cessation
2007
- 2007-05-28 HK HK07105593.3A patent/HK1099016A1/xx not_active IP Right Cessation
- 2007-10-17 HK HK07111210.4A patent/HK1105967A1/xx not_active IP Right Cessation
- 2007-10-24 US US11/877,747 patent/US7786158B2/en active Active
2010
- 2010-07-19 US US12/838,825 patent/US8344011B2/en active Active
2011
- 2011-09-19 HK HK11109830.2A patent/HK1155726A1/xx not_active IP Right Cessation
- 2011-09-28 HR HR20110694T patent/HRP20110694T1/hr unknown
- 2011-10-10 CY CY20111100967T patent/CY1111927T1/el unknown
2012
- 2012-08-14 PH PH12012501640A patent/PH12012501640B1/en unknown
- 2012-11-30 US US13/690,041 patent/US8609709B2/en active Active
2013
- 2013-02-26 IL IL224908A patent/IL224908A/en active IP Right Grant
- 2013-08-22 HR HRP20130800TT patent/HRP20130800T1/hr unknown
- 2013-09-27 HK HK13111031.3A patent/HK1184432A1/xx not_active IP Right Cessation
- 2013-10-03 US US14/045,008 patent/US8772325B2/en active Active
- 2013-11-14 IL IL229444A patent/IL229444A/en active IP Right Grant
2014
- 2014-04-11 AR ARP140101566A patent/AR095848A2/es unknown
- 2014-05-20 US US14/282,828 patent/US9205076B2/en active Active
2015
- 2015-03-18 HR HRP20150305TT patent/HRP20150305T1/hr unknown
- 2015-10-12 US US14/880,597 patent/US9700542B2/en active Active
2016
- 2016-05-30 NO NO20160916A patent/NO20160916A1/no not_active Application Discontinuation
- 2016-10-12 CY CY20161101019T patent/CY1118096T1/el unknown
- 2016-10-12 HR HRP20161331TT patent/HRP20161331T1/hr unknown
2017
- 2017-02-23 NO NO2017007C patent/NO2017007I1/no unknown
- 2017-03-01 LT LTPA2017005C patent/LTC1725537I2/lt unknown
- 2017-03-01 LU LU00007C patent/LUC00007I2/fr unknown
- 2017-03-02 HU HUS1700010C patent/HUS1700010I1/hu unknown
- 2017-03-08 CY CY2017008C patent/CY2017008I1/el unknown
- 2017-03-10 NL NL300865C patent/NL300865I2/nl unknown
- 2017-06-07 US US15/616,358 patent/US10213415B2/en active Active

Also Published As

Publication number	Publication date
ME01601B (me)	2014-09-20
HK1099016A1 (en)	2007-08-03
HRP20130800T1 (en)	2013-09-30
EP1725537B1 (en)	2011-07-13
CA2560047A1 (en)	2005-09-29
ZA200608587B (en)	2008-06-25
CY2017008I2 (el)	2017-11-14
IL178040A (en)	2013-12-31
NO338203B1 (no)	2016-08-08
PT2298744E (pt)	2013-09-12
WO2005090315A1 (en)	2005-09-29
US8772325B2 (en)	2014-07-08
UA86053C2 (ru)	2009-03-25
JP2007529527A (ja)	2007-10-25
EP2573068B1 (en)	2014-12-31
BRPI0508820A (pt)	2007-08-07
LUC00007I1 (es)	2017-03-03
EP2298744A2 (en)	2011-03-23
CN1950342A (zh)	2007-04-18
PL1725537T3 (pl)	2011-12-30
BRPI0508820B1 (pt)	2018-04-10
EP2653465B1 (en)	2016-07-13
US20160030393A1 (en)	2016-02-04
CR8655A (es)	2008-09-09
RS52933B (en)	2014-02-28
US10213415B2 (en)	2019-02-26
SI2653465T1 (sl)	2016-10-28
US8609709B2 (en)	2013-12-17
CN1950342B (zh)	2012-09-26
HUE029852T2 (en)	2017-04-28
US7741356B2 (en)	2010-06-22
CA2560047C (en)	2013-12-24
PT2573068E (pt)	2015-04-27
CY1111927T1 (el)	2015-11-04
HK1155726A1 (en)	2012-05-25
ES2533176T3 (es)	2015-04-08
US20180325870A1 (en)	2018-11-15
TW200539876A (en)	2005-12-16
CY1118096T1 (el)	2017-06-28
US20140256779A1 (en)	2014-09-11
US20100324051A1 (en)	2010-12-23
NO20064660L (no)	2006-12-14
DK3112352T3 (en)	2019-01-28
PL2653465T3 (pl)	2017-01-31
IL229444A0 (en)	2013-12-31
HRP20150305T1 (hr)	2015-04-24
ME02540B (me)	2017-02-20
SI2298744T1 (sl)	2013-10-30
ES2596434T3 (es)	2017-01-09
EP2573068B9 (en)	2015-08-26
US8344011B2 (en)	2013-01-01
HK1184432A1 (en)	2014-01-24
NL300865I2 (nl)	2020-08-17
EP1725537A1 (en)	2006-11-29
RS51995B (en)	2012-04-30
PT1725537E (pt)	2011-09-08
US9205076B2 (en)	2015-12-08
NO2017007I2 (no)	2017-02-23
LTC1725537I2 (lt)	2018-02-26
HUS1700010I1 (hu)	2017-03-28
AU2005224091A1 (en)	2005-09-29
US20130090478A1 (en)	2013-04-11
ES2705077T3 (es)	2019-03-21
BRPI0508820B8 (pt)	2022-11-29
NL300865I1 (nl)	2017-03-14
RS54199B1 (en)	2015-12-31
ME02221B (me)	2016-02-20
JP4778954B2 (ja)	2011-09-21
HRP20161331T1 (hr)	2016-12-30
AU2005224091B2 (en)	2012-02-02
PH12012501640A1 (en)	2015-10-05
LUC00007I2 (es)	2017-05-02
ES2428008T3 (es)	2013-11-05
IL224908A (en)	2015-07-30
SI1725537T1 (sl)	2011-11-30
AR048269A1 (es)	2006-04-12
KR101166342B1 (ko)	2012-07-18
PL2573068T3 (pl)	2015-06-30
SI2573068T1 (sl)	2015-03-31
LTPA2017005I1 (lt)	2017-03-27
MY146972A (en)	2012-10-15
NZ549842A (en)	2010-10-29
ES2367576T3 (es)	2011-11-04
DK1725537T3 (da)	2011-10-31
EP2653465A1 (en)	2013-10-23
DK2653465T3 (da)	2016-08-22
EP3112352A1 (en)	2017-01-04
EP3112352B1 (en)	2018-11-21
TWI361069B (en)	2012-04-01
US20080096888A1 (en)	2008-04-24
US9700542B2 (en)	2017-07-11
RS55122B1 (sr)	2016-12-30
EP2298744B1 (en)	2013-06-26
LT2653465T (lt)	2016-09-12
NO20160916A1 (no)	2006-12-14
MXPA06010642A (es)	2007-03-26
EP2298744A3 (en)	2011-08-10
HK1105967A1 (en)	2008-02-29
AR095848A2 (es)	2015-11-18
PH12012501640B1 (en)	2015-10-05
ECSP066856A (es)	2006-11-24
IL229444A (en)	2017-03-30
PT2653465T (pt)	2016-09-22
US7786158B2 (en)	2010-08-31
EP2573068A1 (en)	2013-03-27
KR20060131983A (ko)	2006-12-20
US20140039024A1 (en)	2014-02-06
NO2017007I1 (no)	2017-02-23
DK2573068T3 (en)	2015-02-16
IL178040A0 (en)	2006-12-31
ATE516274T1 (de)	2011-07-15
CN102786476B (zh)	2017-01-18
US20050203143A1 (en)	2005-09-15
PL2298744T3 (pl)	2013-11-29
CY2017008I1 (el)	2017-11-14
DK2298744T3 (da)	2013-09-02
CN102786476A (zh)	2012-11-21

Publication	Publication Date	Title
HRP20110694T1 (hr)	2011-12-31	Novi spojevi kao modulatori opioidnog receptora
HRP20171028T1 (hr)	2017-10-06	Indolski i indazolski spojevi koji aktiviraju ampk
MX2009008465A (es)	2009-08-20	Nuevas 2-aminooxazolinas como ligandos de taar1.
AU2009320156B2 (en)	2014-02-13	Process for the preparation of protected L-alanine derivatives
PE20141064A1 (es)	2014-09-05	Compuestos de ester boronato y composciones farmaceuticas de los mismos
RU2019131111A (ru)	2021-04-16	ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
HRP20141108T1 (hr)	2015-01-16	Antagonisti piperidinon karboksamid azaindan cgrp receptora
HRP20110958T1 (hr)	2012-01-31	4-fenilaminokinazolin-6-ilamidi
EE9700283A (et)	1998-06-15	Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
RU2018104868A (ru)	2019-09-13	2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
EA200600201A1 (ru)	2006-06-30	Пиперидиновые соединения и фармацевтические композиции, их содержащие
HRP20120762T1 (hr)	2012-10-31	Tetrasupstituirani piridazini kao inhibitori hedgehog puta
AR051471A1 (es)	2007-01-17	Derivados de sulfonamida como moduladores del receptor de glugocorticoides
MX2009009121A (es)	2009-09-03	Aminoamidas como antagonistas de orexina.
HRP20192275T1 (hr)	2020-03-06	Novi spojevi 3,4-dihidro-2h-izokinolin-1-ona i 2,3-dihidro-izoindol-1-ona
EA200300718A1 (ru)	2003-10-30	Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
JP2019519586A5 (es)	2020-12-17
HRP20130918T1 (hr)	2013-11-08	Derivati 4-aminopirimidina kao receptori antagonista histamina h4
JP2005505583A5 (es)	2006-01-05
HRP20100604T1 (hr)	2010-12-31	Derivati 4h-1,2,4-triazin-5-ona, njihova priprava i njihova uporaba kao alfa 7 nikotinskih acetilkolinskih receptora
DK0785789T3 (da)	2003-01-20	Diazepinindoler som phosphodiesterase IV-inhibitorer
MX2012001799A (es)	2012-03-16	Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
SE9904675D0 (sv)	1999-12-20	Novel compounds
EA200602193A1 (ru)	2007-04-27	Меркаптоимидазолы в качестве антагонистов рецептора ccr2
MX2018001486A (es)	2018-03-15	Derivados de etinilo.